MYGN — Myriad Genetics Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.51bn
- $2.45bn
- $753.20m
- 71
- 32
- 100
- 75
2019 June 30th | 2020 June 30th | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 4.6 | -200 | -27.2 | -112 | -263 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 24.6 | 129 | -106 | 85.3 | 83.8 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -37.1 | 115 | 120 | -102 | 10.7 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 83.7 | 60.7 | 18.2 | -106 | -111 |
Capital Expenditures | -8.6 | -10.2 | -18 | -45.3 | -73.3 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -278 | 29.5 | 292 | -32.2 | 105 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -286 | 19.3 | 274 | -77.5 | 31.9 |
Financing Cash Flow Items | -1.4 | -4.9 | -4.5 | -3.7 | -1.7 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 182 | -10 | -151 | -8 | 153 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -17.7 | 70.5 | 141 | -192 | 74.5 |